The pediatric precocious puberty clinic nurse’s communication challenge
Central precocious puberty — the premature activation of the hypothalamic-pituitary-gonadal axis before age eight in girls, with the emergence of breast development, pubic hair, accelerated growth, and advancing bone age — is treated with GnRH agonist therapy to suppress LH, FSH, and estradiol and preserve adult height potential. The treatment works: large cohort studies demonstrate that girls treated with GnRH agonist for CPP achieve adult heights approximately three to five centimeters greater than their untreated predicted adult height, with the effect most pronounced in girls with the youngest age at diagnosis and the most advanced bone age relative to chronological age. The injections or implant are effective, the side effects are manageable, and the clinical outcome evidence is robust.
Yet in the pediatric precocious puberty clinic serving Spanish-speaking families, three adherence errors recur with enough frequency and enough preventable impact on adult height to warrant dedicated, mechanistically grounded family education.
The first is the growth-stop: a father who stops monthly leuprolide injections because his daughter’s growth velocity has decreased from a rapid prepubertal acceleration to a slower prepubertal rate, reasoning that the medication is stunting her growth. This reasoning observes the correct fact — growth rate has decreased — but inverts its meaning. Growth rate decreased because estradiol, which was driving both a premature growth hormone-amplified growth spurt and premature bone plate maturation, has been suppressed. The child who was growing nine centimeters per year and advancing her bone age two years per calendar year was on a trajectory to close her growth plates years ahead of schedule. The child growing four centimeters per year on leuprolide is advancing her bone age at one year per calendar year and will grow for longer. The adult height prediction improves when the growth velocity decreases. The father who stops the medication to “let her grow” is reversing a treatment that was protecting his daughter’s growth potential, not impairing it.
The second is the cure-inference: a mother who stops GnRH agonist depot injections after complete regression of breast development and pubic hair, reasoning that because the signs of precocious puberty are gone, the condition has resolved and the medication is no longer needed. This reasoning attributes the absence of visible puberty signs to disease resolution rather than to the pharmacological mechanism of GnRH agonist action. The agonist works by desensitizing pituitary GnRH receptors through continuous non-pulsatile stimulation, suppressing LH and FSH and dropping estradiol to prepubertal levels. The breast tissue involutes. The pubic hair resolves. The condition has not been cured — the premature hypothalamic GnRH pulse generator that activated at the wrong age is still present and active, held at bay only by the continuous receptor desensitization the agonist provides. When the agonist stops, receptor desensitization reverses within two to four weeks. Pulsatile GnRH resumes driving LH and FSH. Estradiol rises. Breast development re-emerges and bone age advancement resumes at the accelerated CPP rate within months of stopping.
The third is the implant-duration error: a mother who misses her daughter’s Supprelin LA histrelin implant replacement appointment, relying on the continued absence of visible pubic hair or breast development as proof that the implant is still working. The histrelin subdermal implant has a twelve-month FDA-approved delivery duration. After twelve months, histrelin delivery from the depot declines progressively as the reservoir depletes. LH and FSH rebound begins within one to two months of delivery decline. The rebound is detectable on laboratory testing before any secondary sexual characteristic re-emerges — breast budding and pubic hair require weeks of sustained above-threshold estradiol to appear, while the hormonal reactivation and epiphyseal bone age acceleration are already underway. The family who does not see visible pubic hair at fourteen months may be witnessing silent hormonal reactivation and bone maturation that the blood test confirms and the parent cannot.
Three conversations from the pediatric precocious puberty and GnRH agonist clinic:
Scenario 1: Sofía Martínez-García — 7 years old, Houston, Texas
Sofía Martínez-García had been referred to the pediatric endocrinology clinic at age six years and three months when her mother, Rosario García-Torres, noticed that Sofía’s breasts had begun to develop. Rosario had initially assumed this was normal variation — she herself had begun puberty at age nine, younger than average but within the normal range for her family — but when her sister pointed out that breast development before age eight in girls was considered medically early and warranted evaluation, Rosario called the pediatrician. The pediatrician found Tanner III breast development at age six and two months, pubic hair at Tanner I, and a growth velocity of nine centimeters per year over the prior six months, a rate substantially above the normal prepubertal rate of five to six centimeters per year. A left-hand wrist X-ray showed a bone age of nine years — two and three-quarter years ahead of Sofía’s chronological age of six and three months. A GnRH stimulation test produced a peak LH of eleven International Units per liter, clearly above the prepubertal threshold of five IU per liter, confirming central precocious puberty from premature hypothalamic-pituitary axis activation rather than from a peripheral source (an ovarian cyst or exogenous estrogen exposure) that would produce suppressed rather than stimulated LH. MRI of the brain, obtained to rule out a hypothalamic hamartoma or other structural cause, was normal. The diagnosis was idiopathic central precocious puberty.
The pediatric endocrinology nurse, Claudia Herrera-Espinoza, met with Sofía’s parents to discuss treatment. Sofía’s father, Ernesto Martínez-Torres, was a construction contractor who had grown up in Jalisco and come to Houston ten years before Sofía was born. He had not encountered precocious puberty clinically before. His primary concern, as he expressed it to Claudia, was that starting injections on a six-year-old seemed extreme. He asked whether they could wait and see rather than treating. Claudia explained the reasoning for treatment: without treatment, Sofía’s bone age would continue advancing at approximately two years per calendar year, driven by the premature estradiol. By age ten, her bone age would be approximately sixteen years — her growth plates would be as mature as an average sixteen-year-old’s, with very little remaining growth potential. She would likely stop growing at age ten or eleven and reach an adult height of approximately one hundred forty-nine centimeters. With GnRH agonist treatment started now, bone age advancement would slow to the normal rate. She would grow for several more years. Predicted adult height with treatment was approximately one hundred fifty-five centimeters — a six-centimeter improvement that, for a person of Sofía’s expected genetics, was significant. Ernesto and Rosario agreed to begin treatment.
Leuprolide acetate Lupron Depot-Ped 3.75 mg intramuscular injection every twenty-eight days was started at age six and a half. Claudia reviewed the injection schedule, the expected first-month flare response (transient breast tenderness and mild vaginal discharge from the brief initial agonist stimulation before receptor downregulation established suppression), and the expected treatment response: breast tissue regression, pubic hair regression, growth velocity normalization, bone age advancement normalization. At the three-month visit, LH had suppressed to 0.2 IU per liter and estradiol was undetectable — appropriate pharmacological suppression. Breast development was regressing toward Tanner II. Growth velocity was unchanged in the first three months but would be expected to decrease over the next six months as estradiol suppression was sustained. Claudia gave Ernesto and Rosario a written summary of what to expect in Spanish, including the note that growth velocity would decrease and that this was the intended effect, not a problem.
At the eight-month visit, Claudia was the first to notice that Ernesto seemed withdrawn. She asked how things were going at home. Ernesto said he was worried about Sofía. He had been measuring her height every month on the doorframe in the kitchen — a habit from her early childhood — and he had seen her growth slow substantially. Before the injections, she had been shooting up so quickly he could practically see her grow. Now she was barely adding a centimeter between measurements. He had talked to his mother in Guadalajara, who had said that doctors in Mexico sometimes gave growth hormone to children who were not growing enough, and his mother had asked whether they were “killing Sofía’s growth.” He had not mentioned this at the six-month visit because he did not want to seem like he was questioning the doctors. But he had decided to stop the injections. He had not given the seven-month injection. He was not sure he would give the eight-month injection.
Claudia set aside the planned clinical review and focused the visit entirely on the growth velocity conversation. She began by validating what Ernesto had observed: yes, Sofía’s growth had slowed. His measurement on the doorframe was correct. Growth velocity had decreased from approximately nine centimeters per year to approximately four centimeters per year over the eight months of treatment. This was real and he had observed it accurately. And it was the most important clinical sign that the treatment was working.
She explained the mechanism. Sofía’s bone age before treatment was nine years at chronological age six and a half. This meant her growth plates — the cartilage layers at the ends of her long bones where new bone cells were being added — were already as mature as those of a nine-year-old girl. Normal girls have growth plates that age approximately one year for every calendar year. Sofía’s had been aging two years for every calendar year before treatment, because estradiol acts directly on growth plate chondrocytes and accelerates epiphyseal maturation. The growth plates do not know what age a child is. They respond to estrogen. When estrogen is high, they mature and close faster.
Growth plates that close early stop producing new bone, Claudia continued. The total height a person reaches as an adult is determined by how much new bone the growth plates added before they closed. A child whose growth plates close at age ten has only the bone added from birth to age ten — not the bone she would have added from ten to fifteen if her plates had remained open. Before treatment, Sofía was on a path to have her growth plates close around age ten to eleven because they were already as mature as a nine-year-old’s, and if they continued advancing two years per calendar year, they would reach the closure stage (bone age sixteen) by the time Sofía was approximately ten and a half years old. The prediction at that trajectory was an adult height of approximately one hundred forty-nine centimeters.
On Lupron Depot, estradiol was suppressed to prepubertal levels. The premature hormonal signal driving the growth plates to age too fast was removed. Growth plates were now advancing at approximately one year per calendar year — the normal rate. Sofía’s growth plates, currently equivalent to a bone age of approximately nine and a half years (having advanced modestly during the first months of treatment), would now reach closure stage at approximately her chronological age of fifteen to sixteen years if treatment continued. The predicted adult height with continued treatment was now approximately one hundred fifty-five centimeters.
The growth velocity had slowed, Claudia explained, for two reasons. First, estradiol drives the growth hormone-estrogen synergy of the pubertal growth spurt: in a child with untreated CPP, elevated estradiol amplifies growth hormone pulse amplitude at the pituitary, driving IGF-1 to elevated levels and producing the rapid linear growth Ernesto had observed. On Lupron, estradiol was suppressed and growth hormone pulses returned to normal prepubertal amplitude. Growth velocity returned to normal prepubertal rate of four to six centimeters per year. Second, this slower growth rate was now being sustained without the epiphyseal acceleration. A child growing four centimeters per year with bone age advancing one year per calendar year is in a dramatically better position than a child growing nine centimeters per year with bone age advancing two years per calendar year. The ratio that matters is not how fast the child grows — it is how much growth potential remains in the growth plates when the growth slows.
Claudia drew this out on a piece of paper. Two trajectories, both starting with Sofía at age six and a half, bone age nine:
Trajectory A (untreated): bone age advances two years per calendar year. At chronological age ten, bone age sixteen, plates closing, adult height approximately one hundred forty-nine centimeters. Four years of linear growth from age six and a half to ten.
Trajectory B (Lupron): bone age advances one year per calendar year. At chronological age fifteen and a half, bone age sixteen, plates closing, adult height approximately one hundred fifty-five centimeters. Nine years of linear growth from age six and a half to fifteen and a half.
The child on Trajectory A was growing faster — nine centimeters per year — but for only four more years. The child on Trajectory B was growing more slowly — four centimeters per year — but for nine more years. Total height added: Trajectory A adds approximately 36 cm (4 years × 9 cm/year). Trajectory B adds approximately 36-40 cm (9 years × 4-5 cm/year). And starting from the same baseline, the child who started treatment reaches a greater adult height despite the slower growth velocity because she grows for so much longer.
Ernesto was very quiet. He asked: “¿Entonces cuando veo que crece despacio, eso significa que está bien?” (So when I see her growing slowly, that means she is okay?) Yes, Claudia said. Exactly that. The slow growth is the treatment doing its job. The fast growth was the disease doing its damage. Ernesto agreed immediately to restart the injections. The missed month had allowed a modest degree of LH rebound — LH was now 2.8 IU per liter, slightly above the suppressed target of less than 0.5 IU per liter — but bone age had advanced only minimally in one month. The injection was given that visit and the schedule was reset. At the three-month follow-up, LH had re-suppressed to 0.3 IU per liter.
“El medicamento no está frenando el crecimiento de Sofía,” Claudia told Ernesto in the follow-up summary note she gave him to take home. “Está frenando que los huesos de Sofía envejezcan demasiado rápido. La niña que crece rápido con la pubertad temprana va a dejar de crecer a los diez años. La niña que crece despacio con el medicamento va a crecer hasta los quince o dieciséis. La que crece despacio llega más alto.” (The medication is not stopping Sofía’s growth. It is stopping Sofía’s bones from aging too fast. The child who grows fast with early puberty will stop growing at ten. The child who grows slowly with the medication will grow until fifteen or sixteen. The one who grows slowly reaches a greater height.)
Scenario 2: Emma Torres-Cisneros — 8 years old, San Antonio, Texas
Emma Torres-Cisneros had been diagnosed with central precocious puberty at age seven and a half after her mother, Carmen Torres-Espinoza, noticed breast budding that Carmen had initially attributed to a family pattern — Carmen’s mother had undergone early puberty — but which the pediatrician confirmed as Tanner III at age seven and a half. The workup confirmed CPP: bone age ten and a half years at chronological age seven and a half years (three years advanced), LH peak on stimulation test twelve International Units per liter, estradiol forty-eight picograms per milliliter (upper pubertal range), brain MRI normal. Genetic panel sent for academic research purposes detected a variant in GPR54, the receptor for kisspeptin, a neuropeptide that is the master gatekeeper for pubertal GnRH pulse generator activation. The GPR54 variant was classified as a variant of uncertain significance but provided a plausible biological substrate for the premature HPG axis activation.
Treatment was initiated with Lupron Depot-Ped 11.25 mg intramuscular injection every three months. The rationale for the every-three-month formulation over the every-four-week formulation was shared preference for reduced injection frequency and clinical trial data demonstrating equivalent suppression at three months versus one month for most patients. Carmen, a licensed practical nurse who worked in a long-term care facility, was familiar with depot injections professionally and received the treatment plan without concern about the injection itself. Her concern was different: she wanted to understand when Emma would be “better.”
The endocrinology nurse, María Fuentes-Torres, explained that CPP was not a condition that resolved with time in the way an infection resolves. It was a permanent change in the timing of hypothalamic GnRH pulse generator activation that had occurred earlier than expected. GnRH agonist therapy suppressed the consequences — LH, FSH, estradiol, secondary sexual characteristic development, bone age acceleration — but did not modify the underlying mechanism. Treatment would continue until Emma was approximately eight to ten years old or until her bone age had advanced to a point where allowing puberty to proceed was more appropriate than continuing suppression. At that point, the GnRH agonist would be discontinued and puberty would resume. Carmen heard this and asked: “If we stop the injections, will the puberty come back?” María said: yes, within weeks to a few months of stopping, puberty would reactivate and proceed normally. That was the plan — puberty would happen, just at the right time.
At the ten-month visit, the clinical picture was excellent. LH was 0.1 IU per liter — fully suppressed. Estradiol undetectable below the assay threshold of ten picograms per milliliter. Breast tissue: Tanner I — complete regression. Pubic hair: absent. Growth velocity: five and a half centimeters per year — normal prepubertal rate. Bone age: eleven years at chronological age eight and a third — advancing at approximately one year per calendar year, the target rate. Predicted adult height: one hundred fifty-seven centimeters, up from one hundred fifty-one centimeters before treatment.
The clinical team was pleased. Carmen was pleased. She asked María: “La pubertad de Emma ya se quitó completamente, ¿verdad? Los senos desaparecieron, el vello desapareció, todo volvió a ser normal.” (Emma’s puberty is completely gone now, right? The breasts disappeared, the pubic hair disappeared, everything went back to normal.) María said: yes, the treatment is doing exactly what it should. The signs have gone because the medication is working. Emma’s puberty has not disappeared — it has been put on pause. When we stop the medication at the right time, it will resume. Carmen asked: “So it has to continue even though everything looks normal?” Yes, María said. The injections need to continue on schedule.
At the thirteen-month mark — slightly more than two months after the ten-month visit where the next injection had been given — Carmen missed the appointment. She called to reschedule but was placed in a queue. At sixteen months she had not yet rescheduled. At eighteen months she was called by the clinic reminder system and reported that Emma seemed completely fine, had no breast development, no pubic hair, and she had assumed that since everything had resolved and there were no more signs of puberty the treatment had worked and Emma was better. She had not given the thirteen-month injection.
Emma was seen at eighteen months after starting treatment — eight months since the last injection. She was now nine years old. The clinical picture had changed significantly. Breast tissue: Tanner II, new budding under the areola. Pubic hair: Tanner I-II returning. Growth velocity over the two months before the visit: estimated seven centimeters per year, substantially above the prepubertal rate. LH stimulated: thirteen IU per liter. Estradiol: forty-two picograms per milliliter. Bone age: twelve years at chronological age nine years — one and a half year advance in eight months, a rate of more than two years per calendar year. Predicted adult height: one hundred fifty-two centimeters, five centimeters lower than the one hundred fifty-seven centimeter prediction at the ten-month visit with full suppression.
María met with Carmen and began with an acknowledgment: she understood why Carmen had concluded that the treatment had worked and was no longer needed. The breast tissue had completely regressed. The pubic hair had resolved. Emma had looked entirely normal. Carmen had not misread what she saw. She had misread what it meant.
María explained the mechanism of GnRH agonist action in detail. The HPG axis works through a specific architectural feature of the pituitary gonadotrope cell: the GnRH receptor is designed to respond to pulsatile GnRH signal — discrete pulses separated by intervals during which the receptor recovers. When the hypothalamic pulse generator sends a brief pulse of GnRH, the pituitary responds with an LH spike. When the pulse clears, the receptor recovers and is ready for the next pulse. This pulsatile architecture is essential for normal HPG axis function: continuous GnRH exposure shuts it down, while pulsatile GnRH activates it. This is the mechanism the Lupron depot exploits.
The depot injection, María explained, delivers leuprolide at a continuous steady-state level rather than in pulses. The GnRH receptor in Emma’s pituitary was experiencing constant, unvarying receptor stimulation from the depot. This is the pharmacological opposite of the pulsatile pattern the receptor needs to respond with LH secretion. In the presence of continuous stimulation, the pituitary gonadotrope cells downregulate their GnRH receptor expression through a process called homologous desensitization: receptor number decreases, receptor coupling efficiency to intracellular signaling decreases, and cAMP generation per receptor activation decreases. The overall result is that LH and FSH secretion drops to prepubertal levels despite the continuing GnRH signal. Estradiol falls. Secondary sexual characteristics driven by estradiol regress. The growth plates slow their maturation rate. Everything that Carmen observed — breast regression, pubic hair resolution, normalized growth — was the consequence of this pharmacological receptor downregulation, not of the disappearance of the premature HPG axis activation that had originally caused Emma’s CPP.
Emma’s kisspeptin-GPR54 pathway, María continued, was still present in the same state it had been before treatment. The early-activating genetic variant in GPR54 was still present in every hypothalamic kisspeptin neuron. The GPR54 variant that had driven premature kisspeptin signaling to the GnRH pulse generator neurons before treatment was still there. The pituitary receptor downregulation produced by continuous Lupron exposure had blocked the downstream consequences of that premature signaling, but it had not modified the signaling itself. The kisspeptin neurons were still sending their premature activation signal. It was just not getting past the downregulated pituitary receptors.
When the last Lupron injection was given at ten months and no injection was given at thirteen months, the continuous pituitary receptor stimulation was interrupted. The pituitary gonadotrope cells, no longer receiving the constant desensitizing signal, began to resensitize. Receptor expression increased. Receptor coupling efficiency improved. Within two to four weeks of injection discontinuation, the pituitary was responsive again to GnRH. The kisspeptin neurons that had never stopped their premature activation signal now had a responding pituitary to drive. LH and FSH began to rise within weeks of the injection gap. Estradiol rose behind them, reaching pubertal range within one to two months. By the time eight months had passed, LH was at thirteen IU per liter on stimulation, estradiol at forty-two picograms per milliliter, and bone age had advanced a year and a half at the accelerated CPP rate.
Carmen asked: could they recover the ground they had lost? María said: the treatment could be restarted and suppression re-established, and the bone age advancement from the eight-month gap would stop. But the bone age that had advanced during the gap — the year and a half of accelerated maturation that had occurred while the pituitary was unsuppressed — could not be reversed. The predicted adult height was now one hundred fifty-two centimeters. If they had not had the eight-month gap, it would have been one hundred fifty-seven centimeters. The five centimeters lost during the gap were lost from Emma’s adult height potential.
Lupron was restarted at the visit and a plan was made for injections every three months with a specific reminder system — a phone calendar alert, a backup call from the clinic at week ten, and a notation in Emma’s school health file — to ensure no future gaps. At the three-month check, LH was suppressed to 0.3 IU per liter and estradiol was undetectable. The breast budding had regressed again.
“El medicamento de Emma hace que los senos se vayan y que el vello desaparezca,” María said, giving Carmen the frame to use when family members asked why Emma was still getting injections when she looked completely normal. “Pero eso no significa que la pubertad se curó — significa que el medicamento está funcionando. El interruptor que se prendió antes de tiempo en el cerebro de Emma sigue ahí. El medicamento lo está tapando. Cuando paremos las inyecciones, ese interruptor va a prenderse de nuevo. El tratamiento continúa hasta que decidamos juntos que es el momento correcto para que ese interruptor se prenda.” (Emma’s medication makes the breasts go away and the hair disappear. But that does not mean the puberty was cured — it means the medication is working. The switch that turned on too early in Emma’s brain is still there. The medication is covering it. When we stop the injections, that switch will turn on again. Treatment continues until we decide together that it is the right time for that switch to turn on.)
Scenario 3: Valentina Hernández-López — 9 years old, Dallas, Texas
Valentina Hernández-López had been diagnosed with central precocious puberty at age seven and a half when her mother, Elena Hernández-Torres, noticed breast budding. The pediatric endocrinology evaluation confirmed Tanner II breast at age seven and a half, bone age ten years at chronological age seven and a half (two and a half years advanced), LH peak on stimulation test nine International Units per liter, estradiol thirty-two picograms per milliliter, brain MRI normal. The diagnosis was idiopathic CPP.
Elena and Valentina’s father, Marcos Hernández-García, preferred to avoid monthly injections if possible. The endocrinology team discussed the Supprelin LA histrelin acetate subdermal implant — a small cylindrical rod, slightly larger than a grain of rice, placed under the skin of the upper inner arm under local anesthetic in a brief outpatient procedure. The implant delivered sixty-five micrograms of histrelin per day continuously for twelve months, producing the same continuous GnRH receptor desensitization as the monthly or quarterly depot injections. After twelve months, the implant was replaced with a new one under the same outpatient procedure. One procedure per year rather than twelve or four injections.
Elena and Marcos agreed. The implant was placed at age seven and a half. At the six-month check, suppression was complete: LH 0.08 IU per liter, estradiol undetectable, bone age advancing at the appropriate rate, breast tissue regressed to Tanner I, no pubic hair. The clinical team reviewed the twelve-month replacement schedule with Elena and provided a written appointment reminder. Elena noted the date and placed it in her phone calendar.
At the twelve-month mark — the implant replacement appointment — Elena called to reschedule. She explained that Marcos was traveling for work, the children were in back-to-school transition, and she would need to reschedule for two weeks. The clinic confirmed a fourteen-month appointment. Elena did not mark the new date in her phone calendar. At thirteen months she did not come. At fourteen months she received a phone call from the clinic reminder system and came in.
In the car on the way to the clinic, Elena checked Valentina. No breast budding she could see. No pubic hair. She was not growing rapidly — she had not noticed any of the signs she had been told to watch for. She told Valentina that it was probably just a checkup and that the implant seemed to be working fine.
At the clinic, the endocrinology nurse, Ana Cisneros-Espinoza, performed the suppression check before the implant replacement procedure. Serum LH: 6.8 International Units per liter — pubertal range. Estradiol: twenty-eight picograms per milliliter — low pubertal range. Left-hand wrist bone age X-ray: eleven point two years at chronological age nine years. At the prior six-month check, bone age had been approximately nine and a half years at chronological age eight years — so in the twelve months between the six-month check and this visit, bone age had advanced approximately one and seven-tenths years when it should have advanced approximately one year on full suppression. The two-month overage — months thirteen and fourteen without an active implant — was estimated to account for approximately seven-tenths of a year of excess bone age advance compared to the expected trajectory on continued suppression.
Elena was distressed. She had not seen anything from the outside. She had brought Valentina in two months late, but Valentina had seemed completely fine. She had not known the implant had a hard twelve-month limit. She had assumed that if the implant were no longer working she would see the puberty signs come back.
Ana explained the physiology of why the absence of visible puberty signs in months thirteen and fourteen had not meant the implant was still active. The Supprelin LA histrelin implant delivers histrelin from a polymer matrix reservoir. In the first months after placement, drug delivery is consistent as histrelin diffuses from the matrix at the engineered rate. As months pass and the reservoir depletes, delivery begins to taper. By month twelve, the histrelin depot is substantially exhausted and delivery has declined below the threshold concentration needed to maintain continuous pituitary GnRH receptor desensitization. LH and FSH, which had been suppressed by that desensitization, begin to rebound. This rebound is a blood test finding first. Serum LH rises from less than 0.5 IU per liter toward pubertal range. Estradiol follows LH by two to four weeks. Epiphyseal growth plates, responding to rising estradiol, resume their accelerated maturation.
Secondary sexual characteristics, Ana continued, are downstream of estradiol by weeks to months. Breast budding requires sustained estradiol above a threshold — approximately twenty to thirty picograms per milliliter — for approximately four to eight weeks before visible tissue appears under the areola. Pubic hair requires androgen stimulation over a similar period. At fourteen months, Valentina’s estradiol was twenty-eight picograms per milliliter — just entering the threshold range for breast tissue development, but not yet at a level sustained long enough to have produced visible Tanner II changes. Another four to six weeks at this estradiol level would likely have produced detectable breast budding. Elena had not seen it because it had not yet materialized, not because the implant had prevented it.
Meanwhile, the bone age had already been advancing at the accelerated rate during the two-month unprotected window. Growth plates respond to estradiol directly through estrogen receptor alpha in the chondrocytes. They do not wait for visible breast development. The seven-tenths year of excess bone age advance estimated from the two-month gap represented a shortening of the predicted adult height that could not be recovered: those seven-tenths of a year of growth plate maturation had already occurred in the epiphyseal cartilage. The new implant was placed that visit. At the three-month follow-up after replacement, LH was suppressed to 0.2 IU per liter and estradiol was below the assay threshold. Bone age advancement had normalized.
Ana reviewed the twelve-month replacement protocol with Elena and Marcos in detail. The appointment for implant replacement should be treated the same way as the implant placement itself: it was not a routine checkup that could be rescheduled by two months without clinical consequence. It was the procedure that restarted the drug delivery that had just ended. Delaying it was equivalent to having a gap in the injection schedule. The clinic had a robust reminder system and Elena was added to the highest-priority reminder track with calls at ten months, eleven months, and twelve months from the date of each new implant placement. The family was also given a written card to carry with the implant date and the replacement due date, and the school health file was updated with a note that the replacement date was medically scheduled and not deferrable.
Elena asked: were there any symptoms she should watch for at home that would tell her the implant was running out? Ana answered honestly: not reliably. LH and FSH rebound happened before visible secondary sexual characteristics appeared. The laboratory test was the only reliable indicator. Breast budding appearing at home was a late sign of rebound, not an early one. By the time Elena could see it, weeks of unprotected bone age advancement had already occurred. The twelve-month replacement window was the clinical indicator, not the home observation. If Valentina developed any visible pubic hair or breast tissue before the scheduled replacement, Elena should call the clinic immediately and request a same-week appointment and suppression check — it might indicate that the implant had been placed less than optimally, delivering below target levels earlier than expected. But the absence of visible signs was not reassurance that the implant was active past twelve months.
“El implante de Valentina funciona durante doce meses,” Ana said in the written summary she gave Elena for her records. “A los doce meses, el medicamento que tiene adentro se acaba y la señal del cerebro a los ovarios empieza a volver. Eso pasa por dentro — en los análisis de sangre — antes de que se vea nada por fuera. No espere ver los senos o el vello para traerla. La cita a los doce meses es la que pone el siguiente implante. Si la trae tarde, el implante anterior ya no estaba funcionando.” (Valentina’s implant works for twelve months. At twelve months, the medication inside it runs out and the signal from the brain to the ovaries starts to return. That happens on the inside — in blood tests — before anything is visible from the outside. Do not wait to see breasts or pubic hair to bring her. The appointment at twelve months is the one that places the next implant. If you bring her late, the previous implant was no longer working.)
Key Spanish phrases for the pediatric precocious puberty and GnRH agonist clinic
For the opening conversation about what CPP is and why treatment is needed: “La pubertad de Sofía empezó demasiado temprano porque el cerebro mandó una señal antes de lo normal a los ovarios para que produjeran estrógeno. El estrógeno está haciendo que los huesos de Sofía envejezcan rápido. Si los huesos envejecen demasiado rápido, las placas de crecimiento se cierran antes de tiempo y Sofía deja de crecer demasiado pronto. El medicamento frena esa señal para que los huesos no envejezcan antes de tiempo.” (Sofía’s puberty started too early because the brain sent a signal to the ovaries before the normal time to produce estrogen. The estrogen is making Sofía’s bones age quickly. If the bones age too fast, the growth plates close ahead of time and Sofía stops growing too soon. The medication slows that signal so the bones do not age ahead of time.)
For explaining bone age: “La edad ósea es la edad que tienen los huesos, no la que tiene la niña en el calendario. En la radiografía de la muñeca podemos ver si los huesos están envejeciendo más rápido de lo normal. Si la edad ósea va más rápido que la edad del calendario, las placas de crecimiento van a cerrarse antes de tiempo y la estatura de adulta va a ser menor. El medicamento frena el envejecimiento de los huesos para que la niña llegue a su estatura completa.” (Bone age is the age the bones are, not the age the child is on the calendar. In the wrist X-ray we can see whether the bones are aging faster than normal. If bone age is advancing faster than calendar age, the growth plates will close ahead of time and adult height will be less. The medication slows bone aging so the child reaches her full height.)
For explaining why the medication must continue when puberty signs have fully regressed: “Que los senos hayan desaparecido y que no haya vello no significa que la pubertad temprana se curó — significa que el medicamento está funcionando. El interruptor en el cerebro que se prendió antes de tiempo sigue ahí. Cuando paremos el medicamento, ese interruptor se volverá a prender. Tenemos que seguir hasta que sea el momento correcto para que eso pase.” (The fact that the breasts have disappeared and there is no pubic hair does not mean early puberty was cured — it means the medication is working. The switch in the brain that turned on too early is still there. When we stop the medication, that switch will turn on again. We have to continue until it is the right time for that to happen.)
For explaining the growth velocity conversation: “Ver que crece más despacio después del medicamento es buena señal, no mala. Antes del medicamento, el estrógeno la estaba haciendo crecer rápido pero también estaba cerrando los huesos temprano. Ahora crece despacio pero va a crecer por mucho más tiempo y va a llegar más alto de adulta.” (Seeing her grow more slowly after the medication is a good sign, not bad. Before the medication, estrogen was making her grow fast but also closing the bones early. Now she grows slowly but will grow for much longer and will reach a greater adult height.)
For the injection schedule: “Las inyecciones tienen que ponerse exactamente cada cuatro semanas (o cada tres meses para la de tres meses). Si hay retraso de más de unos días, la señal puede volver antes de la próxima inyección. Llame a la clínica si hay algún problema para llegar a la cita — podemos ayudar a encontrar una fecha cercana.” (The injections must be given exactly every four weeks — or every three months for the three-month version. If there is a delay of more than a few days, the signal can return before the next injection. Call the clinic if there is any problem getting to the appointment — we can help find a nearby date.)
For the histrelin implant twelve-month rule: “El implante de Valentina dura doce meses. La cita a los doce meses no es opcional — es cuando se pone el siguiente implante porque el anterior ya no funciona. No espere ver la pubertad para traerla — los cambios en los huesos y en la sangre pasan antes de que se vean los senos o el vello. Doce meses: venga a la cita.” (Valentina’s implant lasts twelve months. The appointment at twelve months is not optional — it is when the next implant is placed because the previous one no longer works. Do not wait to see puberty to bring her — changes in the bones and blood happen before breasts or pubic hair appear. Twelve months: come to the appointment.)
For signs of breakthrough puberty requiring a call during treatment: “Si nota que vuelven a salir los senos, que vuelve el vello en las ingles, que está creciendo muy rápido, o que tiene un sangrado, llame a la clínica durante el horario normal. No son emergencias pero necesitamos revisar si la dosis o el tipo de medicamento necesita ajuste.” (If you notice that breasts are coming back, that pubic hair is returning in the groin, that she is growing very fast, or that she has bleeding, call the clinic during normal hours. These are not emergencies but we need to check whether the dose or type of medication needs adjustment.)
For questions about when treatment will end: “El tratamiento de Emma continúa hasta que la clínica decida que es el momento correcto para su pubertad. Eso depende de su edad, de la edad ósea, y de cuánto lleva en tratamiento. Típicamente paramos entre los ocho y los once años. Lo decidimos juntos con radiografías y análisis — no porque se vea algo por fuera.” (Emma’s treatment continues until the clinic decides the right moment for her puberty. That depends on her age, bone age, and how long she has been on treatment. We typically stop between ages eight and eleven. We decide this together with X-rays and blood tests — not because something looks different from the outside.)